文献速递甲状腺疾病糖尿病

胰岛移植受者停用免疫抑制后迟发自身免疫性甲状腺病

Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本文报告5例1型糖尿病胰岛移植受者在停用维持免疫抑制后出现自身免疫性甲状腺病,其中4例为Graves病甲亢,1例为甲减伴TSH受体抗体阳性,均发生在首次移植后18至135个月、停用免疫抑制后11至18个月。提示尽管常规使用阿仑单抗,临床AITD不常见,但停用免疫抑制后仍需密切监测甲状腺功能。

要点

  • 胰岛移植后停用免疫抑制可迟发自身免疫性甲状腺病
  • 5例均为女性,4例为Graves病甲亢,1例为甲减伴TRAb阳性
  • 建议胰岛移植受者停用免疫抑制后定期监测甲状腺功能

核心结论

  • 尽管胰岛移植受者常规使用阿仑单抗,临床自身免疫性甲状腺病表现似乎不常见,但停用免疫抑制后仍可发生,需仔细监测甲状腺功能。

研究设计与样本

  • 病例系列描述5例因1型糖尿病接受胰岛移植后发生自身免疫性甲状腺病的女性患者。
  • 4例在至少一次胰岛输注前接受阿仑单抗20至40 mg,1例接受抗胸腺细胞球蛋白诱导。

主要发现

  • 自身免疫性甲状腺病出现在首次移植后18至135个月,以及停用所有维持免疫抑制后11至18个月。
  • 4例表现为Graves病相关的临床和生化甲亢,1例表现为生化甲减和TSH受体抗体阳性。
  • 所有患者均接受自身免疫性甲状腺病的常规治疗。

临床怎么用

  • 对胰岛移植受者,尤其在停用维持免疫抑制后,应进行仔细的甲状腺功能监测。
  • 出现甲亢或甲减表现时,应考虑自身免疫性甲状腺病并按常规治疗。

局限性

  • 仅为5例病例描述,无法确定自身免疫性甲状腺病的发生率或危险因素。
  • 未报告甲状腺功能具体数值、抗体滴度及治疗转归细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Clinical islet transplantation (CIT) is an innovative strategy to treat highly selected individuals with type 1 diabetes mellitus (T1DM). Lymphodepletion with alemtuzumab or thymoglobulin is often used for induction therapy in CIT. Alemtuzumab was recently licensed as a treatment of relapsing remitting multiple sclerosis (RRMS). In RRMS, autoimmune thyroid disease (AITD) has developed in up to 40% of individuals treated with alemtuzumab. The appearance of AITD after CIT is not well described. We herein explore factors associated with AITD developing after CIT and any relationship with exposure to lymphodepleting antibodies (alemtuzumab or thymoglobulin). CASE DESCRIPTION: Five cases of AITD developing after CIT for T1DM are described. All were female. Four cases had received alemtuzumab (20 to 40 mg) prior to at least one islet infusion, and one received thymoglobulin induction. The presentation with AITD was 18 to 135 months after first transplant and 11 to 18 months after withdrawal of all maintenance immunosuppression (IS). Four cases presented with clinical and biochemical evidence of hyperthyroidism from Graves disease. One case presented with biochemical evidence of hypothyroidism and positive TSH receptor antibodies. All were treated with conventional therapies for AITD. CONCLUSIONS: Despite routine use of alemtuzumab, clinical presentations of AITD seem to be uncommon in patients with CIT receiving IS. However, AITD can develop after withdrawal of IS, highlighting the need for careful thyroid surveillance in this population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dunn A, Lam A, Hidalgo L, et al. Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion. J Clin Endocrinol Metab. 2019. PMID: 30398662. doi:10.1210/jc.2018-01652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。